<DOC>
	<DOCNO>NCT02197234</DOCNO>
	<brief_summary>This Phase I , open-label , 2-part study patient confirm diagnosis epidermal growth factor receptor ( EGFR ) mutation positive ( EGFRm+ ) non-small cell lung cancer ( NSCLC ) , progress follow prior therapy approve EGFR tyrosine kinase inhibitor ( TKI ) agent . Part A assess effect AZD9291 pharmacokinetic ( PK ) parameter simvastatin simvastatin acid , follow multiple oral dose AZD9291 fast state . Part B allow patient access AZD9291 PK phase ( Part A ) provide additional safety data collection . All patient Part A complete treatment may continue receive AZD9291 80 mg daily : disease progression ; longer derive clinical benefit ; reason .</brief_summary>
	<brief_title>Study Assess Effect AZD9291 Blood Levels Simvastatin Patients With EGFRm+ NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Osimertinib</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>For inclusion study patient fulfil follow criterion : 1 . Male female , age least 18 year . 2 . Histological cytological confirmation diagnosis NSCLC . 3 . Radiological documentation disease progression previous continuous treatment EGFR TKI , eg gefitinib , afatinib erlotinib . In addition , line therapy may give . All patient must document radiological progression last treatment administer prior enrol study . 4 . Confirmation tumour harbour EGFR mutation know associated EGFR TKI sensitivity ( include G719X , exon 19 deletion , L858R , L861Q ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 deterioration previous 2 week ( Appendix G ) . 6 . Patients must life expectancy â‰¥12 week estimate time screening . 7 . Females use adequate contraceptive measure must negative pregnancy test prior start dose childbearing potential , must evidence nonchildbearing potential fulfil one follow criterion screen : Postmenopausal define age 50 year amenorrhoeic least 12 month follow cessation exogenous hormonal treatment ; woman 50 year old would consider postmenopausal amenorrhoeic 12 month follow cessation exogenous hormonal treatment LH FSH level postmenopausal range institution ; documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation . 8 . Male patient willing use barrier contraception , ie , condom , 6 month last study drug take . Exclusion criterion : 1 . Participation another study IP last 14 day ( long period depend defined characteristic agent use ) . 2 . Treatment follow : Treatment EGFR TKI ( eg , erlotinib gefitinib ) within 8 day approx . 5 x halflife , whichever longer , first dose study treatment ; cytotoxic chemotherapy , investigational agent anticancer drug previous treatment regimen clinical study within 14 day first dose ; major surgery ( exclude placement vascular access ) within 4 week first dose study treatment ; radiotherapy limit field radiation palliation within 1 week first dose study treatment , exception patient receive radiation 30 % bone marrow wide field radiation must complete within 4 week first dose ; patient currently receive ( unable stop use prior receiving first dose study treatment ) medication herbal supplement know potent inhibitor CYP3A4 ( least 1 week prior ) potent inducer CYP3A4 ( least 3 week prior ) . All patient must avoid concomitant use medication , herbal supplement and/or ingestion food know inducer/inhibitory effect CYP3A4 . 3 . Any unresolved toxicity prior therapy great CTCAE Grade 1 time start study treatment exception alopecia Grade 2 , prior platinumtherapy relate neuropathy . 4 . Any intake grapefruit , grapefruit juice , Seville oranges , Seville orange marmalade , product contain grapefruit Seville oranges within 7 day first administration IP final PK sample collection Day 32 Part A . 5 . Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 4 week prior start study treatment . 6 . Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension active bleeding diatheses , PI 's opinion make undesirable patient participate study would jeopardise compliance protocol , active infection include hepatitis B , hepatitis C , HIV . Screening chronic condition require . 7 . Inadequate bone marrow reserve organ function demonstrate follow laboratory value : ANC &lt; 1.5 x 10^9/L ; platelet count &lt; 100 x 10^9/L ; haemoglobin &lt; 90 g/L ; ALT &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastases ; Aspartate aminotransferase ( AST ) &gt; 2.5 time ULN demonstrable liver metastasis &gt; 5 time ULN presence liver metastases ; total bilirubin &gt; 1.5 time ULN liver metastases &gt; 3 time ULN presence document Gilbert 's Syndrome ( unconjugated hyperbilirubinaemia ) liver metastasis ; creatinine &gt; 1.5 time ULN concurrent creatinine clearance &lt; 50 ml/min ( measure calculate Cockcroft Gault equation ) ; confirmation creatinine clearance require creatinine &gt; 1.5 time ULN . 8 . Any following cardiac criterion : mean rest correct QT interval correct heart rate use Fridericia 's correction factor ( QTcF ) &gt; 470 msec obtain 3 ECGs ; clinically important abnormality rhythm , conduction morphology rest ECG eg , complete leave bundle branch block , third degree heart block , second degree heart block , PR interval &gt; 250 msec ; factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death age 40 concomitant medication know prolong QT interval . 9 . Patients unable swallow oral medication patient GI disorder significant GI resection likely interfere absorption AZD9291 . 10 . Past medical history ILD , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD . 11 . Women breastfeed . 12 . Patients know hypersensitivity AZD9291 , simvastatin , excipients product . 13 . Concomitant medication contraindicate use simvastatin due drug interaction associate increase risk rhabdomyolysis ( include , limited ) : itraconazole , ketoconazole , posaconazole , erythromycin , clarithromycin , telithromycin , HIV protease inhibitor ( eg , nelfinavir ) , nefazodone , cyclosporine , danazol , gemfibrozil , amiodarone , amlodipine . 14 . 3hydroxy3methylglutaryl coenzyme A ( HMGCoA ) reductase inhibitor , lovastatin simvastatin . 15 . For optional genetic research : Previous allogenic bone marrow transplant nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oncology , cancer , non small cell lung cancer , anticancer drug , pharmacokinetics , AZD9291 , simvastatin , EGFR gene</keyword>
</DOC>